(Circulation. 1995;91:145-153.)
© 1995 American Heart Association, Inc.
Effects of Chronic Systemic Administration of Basic Fibroblast Growth Factor on Collateral Development in the Canine Heart
Presented in part at the 66th Annual Scientific Sessions of the American Heart Association, Atlanta, Ga, November 8-11, 1993.
From the Section of Experimental Physiology and Pharmacology, Cardiology Branch (D.F.L., M.S., M.S., E.H., M.A.S.R., J.A.S., S.E.E., E.F.U.), the Biostatistics Research Branch (S.H.), and the Pathology Branch (R.C.), National Heart, Lung, and Blood Institute, and the National Eye Institute (W.G.R.), National Institutes of Health, Bethesda, Md.
Correspondence to Ellis F. Unger, MD, 
Senior Investigator,
Cardiology Branch, NHLBI, Bldg 10, Room 7B15, National Institutes of Health,
Bethesda, MD 20892.
Background Recently we reported that intracoronary administration of basic fibroblast growth factor (bFGF), a potent angiogenic peptide, increases collateral blood flow in dogs subjected to progressive left circumflex coronary artery (LCx) occlusion. The aim of the present study was to examine the effect of systemically administered bFGF on collateral blood flow and to assess its pharmacokinetics and potential side effects.
Methods and Results Forty-seven dogs were subjected to progressive ameroid-induced occlusion of the LCx, an intervention known to induce the development of collateral vessels. In phase I of the investigation, dogs were randomized to receive bFGF 1.74 mg/d (n=10) or saline (n=9) as a left atrial injection for 4 weeks. Relative collateral blood flow was assessed serially with radiolabeled microspheres in the conscious state during maximal coronary vasodilatation. Initiation of bFGF treatment was temporally associated with a marked acceleration of collateral development; however, collateral flow in control dogs improved toward the end of the study, approaching that of bFGF-treated dogs at the 38-day end point. Phase II of the investigation was a three-armed study of extended duration to determine whether bFGF caused a sustained increase in collateral function. Dogs were randomized to receive bFGF 1.74 mg/d for 9 weeks (n=7), bFGF 1.74 mg/d for 5 weeks followed by placebo for 4 weeks (n=11), or placebo for 9 weeks (n=10). Relative and absolute collateral blood flow were assessed serially with microspheres during maximal coronary vasodilatation. Between the 10th and 17th days after ameroid placement, bFGF-treated dogs exhibited marked improvement in collateral flow such that maximal collateral conductance exceeded that of controls by 24% at the 5-week crossover point. Final collateral conductance was similar in dogs receiving bFGF for 5 and 9 weeks despite withdrawal of treatment in the former group. bFGF administration was associated with a 21% increase in final collateral conductance as well as a 49% increase in collateral zone vascular density. Prolonged bFGF administration was also associated with a decrease in arterial pressure, moderate thrombocytopenia, and moderate, reversible anemia.
Conclusions Systemic administration of bFGF enhanced collateral conductance in dogs with progressive single-vessel coronary occlusion. The beneficial effect of bFGF occurred primarily between the 7th and 14th days of therapy, and regression of collateral development was not noted after withdrawal of treatment. The present investigation provides impetus to the concept that collateral development can be enhanced pharmacologically–specifically by bFGF–raising the possibility that such an intervention might eventually be applied clinically.
Key Words: circulation • pharmacokinetics • peptides • growth substances
This article has been cited by other articles:
 |
|
 |
|
  K. A. Horvath and Y. Zhou Transmyocardial Laser Revascularization and Extravascular Angiogenetic Techniques to Increase Myocardial Blood Flow Card. Surg. Adult, January 1, 2008; 3(2008): 733 - 752. [Full Text]
|
|
|
|
 |
|
 I. Eitenmuller, O. Volger, A. Kluge, K. Troidl, M. Barancik, W.-J. Cai, M. Heil, F. Pipp, S. Fischer, A. J.G. Horrevoets, et al. The Range of Adaptation by Collateral Vessels After Femoral Artery Occlusion Circ. Res., September 15, 2006; 99(6): 656 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Lamping, W. Zheng, D. Xing, L. P. Christensen, J. Martins, and R. J. Tomanek Bradycardia Stimulates Vascular Growth During Gradual Coronary Occlusion Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2122 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Wamsley, U. T. Iwaniec, and T. J. Wronski Selected Extraskeletal Effects of Systemic Treatment with Basic Fibroblast Growth Factor in Ovariectomized Rats Toxicol Pathol, August 1, 2005; 33(5): 577 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Morino, T. Nakamura, T. Toba, M. Takahashi, T. Kushibiki, Y. Tabata, and Y. Shimizu Fibroblast Growth Factor-2 Induces Recovery of Pulmonary Blood Flow in Canine Emphysema Models Chest, August 1, 2005; 128(2): 920 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Krombach, J. G. Pfeffer, S. Kinzel, M. Katoh, R. W. Gunther, and A. Buecker MR-guided Percutaneous Intramyocardial Injection with an MR-compatible Catheter: Feasibility and Changes in T1 Values after Injection of Extracellular Contrast Medium in Pigs Radiology, May 1, 2005; 235(2): 487 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Suzuki, T.-C. Lee, J. A. Fallavollita, and J. M. Canty Jr Adenoviral Gene Transfer of FGF-5 to Hibernating Myocardium Improves Function and Stimulates Myocytes to Hypertrophy and Reenter the Cell Cycle Circ. Res., April 15, 2005; 96(7): 767 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Filion and A. S. Popel Intracoronary administration of FGF-2: a computational model of myocardial deposition and retention Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H263 - H279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saeed, R. Lee, A. Martin, O. Weber, G. A. Krombach, S. Schalla, M. Lee, D. Saloner, and C. B. Higgins Transendocardial Delivery of Extracellular Myocardial Markers by Using Combination X-ray/MR Fluoroscopic Guidance: Feasibility Study in Dogs Radiology, June 1, 2004; 231(3): 689 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sakakibara, K. Tambara, G. Sakaguchi, F. Lu, M. Yamamoto, K. Nishimura, Y. Tabata, and M. Komeda Toward surgical angiogenesis using slow-released basic fibroblast growth factor Eur. J. Cardiothorac. Surg., July 1, 2003; 24(1): 105 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ruel, R. A. Kelly, and F. W. Sellke Therapeutic Angiogenesis, Transmyocardial Laser Revascularization, and Cell Therapy Card. Surg. Adult, January 1, 2003; 2(2003): 715 - 750. [Full Text]
|
|
|
|
 |
|
 S. B. Freedman and J. M. Isner Therapeutic Angiogenesis for Coronary Artery Disease Ann Intern Med, January 1, 2002; 136(1): 54 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Tabibiazar and S.G Rockson Angiogenesis and the ischaemic heart Eur. Heart J., June 1, 2001; 22(11): 903 - 918. [PDF]
|
|
|
|
 |
|
 S. Fuchs, R. Baffour, Y. F. Zhou, M. Shou, A. Pierre, F. O. Tio, N. J. Weissman, M. B. Leon, S. E. Epstein, and R. Kornowski Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1726 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F Unger Experimental evaluation of coronary collateral development Cardiovasc Res, February 16, 2001; 49(3): 497 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Post, R. Laham, F. W. Sellke, and M. Simons Therapeutic angiogenesis in cardiology using protein formulations Cardiovasc Res, February 16, 2001; 49(3): 522 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Epstein, S. Fuchs, Y. F. Zhou, R. Baffour, and R. Kornowski Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards Cardiovasc Res, February 16, 2001; 49(3): 532 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. S. Kyriakides, P. Petinakis, L. Kaklamanis, E. Sbarouni, P. Karayannakos, D. Iliopoulos, I. Dontas, and D. Th. Kremastinos Intramuscular administration of estrogen may promote angiogenesis and perfusion in a rabbit model of chronic limb ischemia Cardiovasc Res, February 16, 2001; 49(3): 626 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kroon, P Koolwijk, B van der Vecht, and V. van Hinsbergh Hypoxia in combination with FGF-2 induces tube formation by human microvascular endothelial cells in a fibrin matrix: involvement of at least two signal transduction pathways J. Cell Sci., January 2, 2001; 114(4): 825 - 833. [Abstract] [PDF]
|
|
|
|
|
|
R. J. Laham, N. A. Chronos, M. Pike, M. E. Leimbach, J. E. Udelson, J. D. Pearlman, R. I. Pettigrew, M. J. Whitehouse, C. Yoshizawa, and M. Simons Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2132 - 2139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Udelson, V. Dilsizian, R. J. Laham, N. Chronos, J. Vansant, M. Blais, J. R. Galt, M. Pike, C. Yoshizawa, and M. Simons Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease Circulation, October 3, 2000; 102(14): 1605 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Lazarous, E. F. Unger, S. E. Epstein, A. Stine, J. L. Arevalo, E. Y. Chew, and A. A. Quyyumi Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1239 - 1244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Montrucchio, G. Alloatti, and G. Camussi Role of Platelet-Activating Factor in Cardiovascular Pathophysiology Physiol Rev, October 1, 2000; 80(4): 1669 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Mallery, P. Pei, J. Kang, G. Zhu, G. M. Ness, and S. P. Schwendeman Sustained angiogenesis enables in vivo transplantation of mucocutaneous derived AIDS-related Kaposi's sarcoma cells in murine hosts Carcinogenesis, September 1, 2000; 21(9): 1647 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fernandez, A. Buehler, S. Wolfram, S. Kostin, G. Espanion, W. M. Franz, H. Niemann, P. A. Doevendans, W. Schaper, and R. Zimmermann Transgenic Myocardial Overexpression of Fibroblast Growth Factor-1 Increases Coronary Artery Density and Branching Circ. Res., August 4, 2000; 87(3): 207 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Hampton, I. Amende, J. Fong, V. E. Laubach, J. Li, C. Metais, and M. Simons Basic FGF reduces stunning via a NOS2-dependent pathway in coronary-perfused mouse hearts Am J Physiol Heart Circ Physiol, July 1, 2000; 279(1): H260 - H268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Corseaux, T. Meurice, I. Six, L. Rugeri, M. D. Ezekowitz, P. Rouvier, R. Bordet, C. Bauters, and B. Jude Basic Fibroblast Growth Factor Increases Tissue Factor Expression in Circulating Monocytes and in Vascular Wall Circulation, April 25, 2000; 101(16): 2000 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kornowski, M. B. Leon, S. Fuchs, Y. Vodovotz, M. A. Flynn, D. A. Gordon, A. Pierre, I. Kovesdi, J. A. Keiser, and S. E. Epstein Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy: Results in normal and ischemic porcine models J. Am. Coll. Cardiol., March 15, 2000; 35(4): 1031 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. S. Rajanayagam, M. Shou, V. Thirumurti, D. F. Lazarous, A. A. Quyyumi, L. Goncalves, J. Stiber, S. E. Epstein, and E. F. Unger Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs J. Am. Coll. Cardiol., February 1, 2000; 35(2): 519 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Laham, M. Rezaee, M. Post, D. Novicki, F. W. Sellke, J. D. Pearlman, M. Simons, and D. Hung Intrapericardial Delivery of Fibroblast Growth Factor-2 Induces Neovascularization in a Porcine Model of Chronic Myocardial Ischemia J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 795 - 802. [Abstract] [Full Text]
|
|
|
|
|
|
R. Kornowski, S. Fuchs, M. B. Leon, and S. E. Epstein Delivery Strategies to Achieve Therapeutic Myocardial Angiogenesis Circulation, February 1, 2000; 101(4): 454 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Chen, W. Jiang, D. P. Via, S. Luo, T.-R. Li, Y.-T. Lee, and P. D. Henry Oxidized Low-Density Lipoproteins Inhibit Endothelial Cell Proliferation by Suppressing Basic Fibroblast Growth Factor Expression Circulation, January 18, 2000; 101(2): 171 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Schaper Quo vadis collateral blood flow?: A commentary on a highly cited paper Cardiovasc Res, January 1, 2000; 45(1): 220 - 223. [Full Text] [PDF]
|
|
|
|
|
|
M. Fleisch, M. Billinger, F. R. Eberli, A. R. Garachemani, B. Meier, and C. Seiler Physiologically Assessed Coronary Collateral Flow and Intracoronary Growth Factor Concentrations in Patients With 1- to 3-Vessel Coronary Artery Disease Circulation, November 9, 1999; 100(19): 1945 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Laham, M. Rezaee, M. Post, F. W. Sellke, R. A. Braeckman, D. Hung, and M. Simons Intracoronary and Intravenous Administration of Basic Fibroblast Growth Factor: Myocardial and Tissue Distribution Drug Metab. Dispos., July 1, 1999; 27(7): 821 - 826. [Abstract] [Full Text]
|
|
|
|
|
|
J. R Kersten, P. S Pagel, W. M Chilian, and D. C Warltier Multifactorial basis for coronary collateralization: a complex adaptive response to ischemia Cardiovasc Res, July 1, 1999; 43(1): 44 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hasegawa, A. Kimura, M. Miyataka, M. Inagaki, and K. Ishikawa Basic Fibroblast Growth Factor Increases Regional Myocardial Blood Flow and Salvages Myocardium in the Infarct Border Zone in a Rabbit Model of Acute Myocardial Infarction Angiology, June 1, 1999; 50(6): 487 - 495. [Abstract] [PDF]
|
|
|
|
|
|
K. A. Detillieux, J. T. A. Meij, E. Kardami, and P. A. Cattini alpha 1-Adrenergic stimulation of FGF-2 promoter in cardiac myocytes and in adult transgenic mouse hearts Am J Physiol Heart Circ Physiol, March 1, 1999; 276(3): H826 - H833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Laham, M. Simons, M. Tofukuji, D. Hung, and F. W. Sellke MODULATION OF MYOCARDIAL PERFUSION AND VASCULAR REACTIVITY BY PERICARDIAL BASIC FIBROBLAST GROWTH FACTOR: INSIGHT INTO ISCHEMIA-INDUCED REDUCTION IN ENDOTHELIUM-DEPENDENT VASODILATATION J. Thorac. Cardiovasc. Surg., December 1, 1998; 116(6): 1022 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Miyataka, K. Ishikawa, and R. Katori Basic Fibroblast Growth Factor Increased Regional Myocardial Blood Flow and Limited Infarct Size of Acutely Infarcted Myocardium in Dogs Angiology, May 1, 1998; 49(5): 381 - 390. [Abstract] [PDF]
|
|
|
|
|
|
R. J. Tomanek, K. Lotun, E. B. Clark, P. R. Suvarna, and N. Hu VEGF and bFGF stimulate myocardial vascularization in embryonic chick Am J Physiol Heart Circ Physiol, May 1, 1998; 274(5): H1620 - H1626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Tomanek, M. K. Doty, and A. Sandra Early Coronary Angiogenesis in Response to Thyroxine : Growth Characteristics and Upregulation of Basic Fibroblast Growth Factor Circ. Res., March 23, 1998; 82(5): 587 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Lopez, E. R. Edelman, A. Stamler, M. G. Hibberd, P. Prasad, K. A. Thomas, J. Disalvo, R. P. Caputo, J. P. Carrozza, P. S. Douglas, et al. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia Am J Physiol Heart Circ Physiol, March 1, 1998; 274(3): H930 - H936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Waltenberger Modulation of Growth Factor Action : Implications for the Treatment of Cardiovascular Diseases Circulation, December 2, 1997; 96(11): 4083 - 4094. [Abstract] [Full Text]
|
|
|
|
|
|
H. Ueno, J.-J. Li, S. Masuda, Z. Qi, H. Yamamoto, and A. Takeshita Adenovirus-Mediated Expression of the Secreted Form of Basic Fibroblast Growth Factor (FGF-2) Induces Cellular Proliferation and Angiogenesis In Vivo Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2453 - 2460. [Abstract] [Full Text]
|
|
|
|
|
|
A. L. Wong, Z. A. Haroon, S. Werner, M. W. Dewhirst, C. S. Greenberg, and K. G. Peters Tie2 Expression and Phosphorylation in Angiogenic and Quiescent Adult Tissues Circ. Res., October 19, 1997; 81(4): 567 - 574. [Abstract] [Full Text]
|
|
|
|
|
|
G. Melillo, M. Scoccianti, I. Kovesdi, J. Safi Jr, T. Riccioni, and M. C Capogrossi Gene therapy for collateral vessel development Cardiovasc Res, September 1, 1997; 35(3): 480 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Chen, J. Cartwright Jr, Z. Li, S. Lou, H. H. Nguyen, A. M. Gotto Jr, and P. D. Henry Inhibitory Effects of Hypercholesterolemia and Ox-LDL on Angiogenesis-like Endothelial Growth in Rabbit Aortic Explants : Essential Role of Basic Fibroblast Growth Factor Arterioscler. Thromb. Vasc. Biol., July 1, 1997; 17(7): 1303 - 1312. [Abstract] [Full Text]
|
|
|
|
|
|
M. S. Pepper Manipulating Angiogenesis: From Basic Science to the Bedside Arterioscler. Thromb. Vasc. Biol., April 1, 1997; 17(4): 605 - 619. [Abstract] [Full Text]
|
|
|
|
|
|
P. Whittaker and R. A. Kloner Transmural Channels as a Source of Blood Flow to Ischemic Myocardium?: Insights From the Reptilian Heart Circulation, March 18, 1997; 95(6): 1357 - 1359. [Full Text]
|
|
|
|
|
|
J.-W. Gu, D. Santiago, Y. Olowe, and J. Weinberger Basic Fibroblast Growth Factor as a Biochemical Marker of Exercise-Induced Ischemia Circulation, March 4, 1997; 95(5): 1165 - 1168. [Abstract] [Full Text]
|
|
|
|
|
|
W. Schaper and W. D. Ito Molecular Mechanisms of Coronary Collateral Vessel Growth Circ. Res., November 1, 1996; 79(5): 911 - 919. [Full Text]
|
|
|
|
|
|
M. C.G. Horrigan, A. I. MacIsaac, F. A. Nicolini, D. G. Vince, P. Lee, S. G. Ellis, and E. J. Topol Reduction in Myocardial Infarct Size by Basic Fibroblast Growth Factor After Temporary Coronary Occlusion in a Canine Model Circulation, October 15, 1996; 94(8): 1927 - 1933. [Abstract] [Full Text]
|
|
|
|
|
|
C. Chen, S. G. Mattar, J. D. Hughes, G. F. Pierce, J. E. Cook, D. N. Ku, S. R. Hanson, and A. B. Lumsden Recombinant Mitotoxin Basic Fibroblast Growth Factor–Saporin Reduces Venous Anastomotic Intimal Hyperplasia in the Arteriovenous Graft Circulation, October 15, 1996; 94(8): 1989 - 1995. [Abstract] [Full Text]
|
|
|
|
|
|
J. Waltenberger, U. Mayr, S. Pentz, and V. Hombach Functional Upregulation of the Vascular Endothelial Growth Factor Receptor KDR by Hypoxia Circulation, October 1, 1996; 94(7): 1647 - 1654. [Abstract] [Full Text]
|
|
|
|
|
|
D. F. Lazarous, M. Shou, M. Scheinowitz, E. Hodge, V. Thirumurti, A. N. Kitsiou, J. A. Stiber, A. D. Lobo, S. Hunsberger, E. Guetta, et al. Comparative Effects of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor on Coronary Collateral Development and the Arterial Response to Injury Circulation, September 1, 1996; 94(5): 1074 - 1082. [Abstract] [Full Text]
|
|
|
|
|
|
M. Fujita, M. Ikemoto, M. Kishishita, H. Otani, R. Nohara, T. Tanaka, S.-i. Tamaki, A. Yamazato, and S. Sasayama Elevated Basic Fibroblast Growth Factor in Pericardial Fluid of Patients With Unstable Angina Circulation, August 15, |